17/10/2001
London, UK – 17th October 2001: ReGen Therapeutics Plc (“ReGen” or the “Company”), a company developing a potential treatment for Alzheimer’s disease, is pleased to announce that it has now conditionally placed 10,489,627 new ordinary shares at 10p per new ordinary share pursuant to the placing announced on 11 October 2001 (“Placing”). The Placing is, inter alia, conditional on approval of Shareholders at an Extraordinary General Meeting of the Company to be held on 5 November 2001. The results of the Placing and the Extraordinary General Meeting will be published after conclusion of the Extraordinary General Meeting. The Placing list has now closed.
Percy Lomax, Chairman, commented, “I am delighted that the Company has managed to achieve this level of conditional commitments in the current difficult market conditions. The funds raised pursuant to the placing, will enable us to continue our current activities, including completion of the Clinical Trial in Poland”.
For further information, please contact:
BUCHANAN COMMUNICATIONS
Lisa Baderoon
lisab@buchanan.uk.com
Tel No: 020 7466 5000
M: 07721 413496
This press release does not constitute or form part of any offer or invitation to purchase, subscribe for or sell any shares or other securities in ReGen nor shall it or any part of it or the fact of its publication form the basis of, or be relied on in connection with, any contract therefore.